Abstract 12579: Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Abstract
The EMPA-REG OUTCOME trial reported cardioprotective effects of empagliflozin (EMPA) in patients with established cardiovascular diseases (CVD). We evaluated the association between EMPA and the risk of cardiovascular events, versus GLP1 receptor agonist (GLP-1RA) or DPP4 inhibitor (DPP-4i) in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) study of type 2 diabetes (T2D) patients in routine care, updating a prior analysis using data from 08/2014 through 09/2018. Using 2 commercial and Medicare claims databases, we identified 88,826 pairs of 1:1 propensity score-matched (PSM) T2D patients ≥18 years initiating EMPA or a GLP-1RA [Cohort 1], and 69,610 pairs initiating EMPA or a DPP-4i [Cohort 2]. Our outcomes were (i) a composite of atherosclerotic cardiovascular diseases (ASCVD): MI, stroke, unstable angina and coronary revascularization and (ii) heart failure hospitalization in primary discharge (HHF-Primary) or any position (HHF-Any). In each cohort, we estimated hazard ratios (HR) and 1-year numbers needed to treat (NNT), accounting for death as a competing risk, pooled across databases adjusting for >140 baseline covariates. After PSM, exposure groups had similar characteristics (Table 1). Compared to GLP-1RA, EMPA had a similar risk of ASCVD [HR (95% CI): 1.05 (0.96,1.15)] and a decreased risk of HHF-Primary: 0.64 (0.54,0.76) and HHF-Any: 0.83 (0.77,0.90). One-year NNTs for EMPA vs GLP-1RA were 235 for HHF-Primary and 133 for HHF-Any. Results for EMPA vs…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.